Natco Pharma Launched a Generic Version of Celgene’s Pomalyst in US 

Natco Pharma Ltd said on Tuesday, 3 March, that it and its partner Breckenridge Pharmaceutical have introduced Pomalidomide capsules, a generic version of Celgene’s Pomalyst, in the United States.

The capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of the completion of the most recent therapy, according to the company.

It is also licensed for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma, according to the statement.

The medicine comes in 1mg, 2mg, 3mg, and 4mg dosages and is largely marketed through specialist pharmacies and clinics.

According to industry sales data, the capsules had an anticipated sales value of $3.2 billion in the United States for the 12 months ending September 2025.

Natco Pharma believes it has 180 days of shared exclusivity, according to documents released by the US Food and Drug Administration.

The company’s vice-chairman and CEO, Rajeev Nannapeneni, stated that the launch boosts the company’s oncology and specialty portfolio in the United States.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

The post Natco Pharma Launched a Generic Version of Celgene’s Pomalyst in US  appeared first on Equitypandit.